On this page

tretinoin

Prescription ANDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Tretinoin
Generic name
tretinoin
Dosage form
Cream
Route
Topical
Marketing category
ANDA · ANDA
Labeler
A-S Medication Solutions
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
3
NDC product codes
42
Packages
67
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Tretinoin .25 mg/g 106302 View
Tretinoin .5 mg/g 106302 View
Tretinoin 1 mg/g 106302 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
109

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Retinoid [EPC] EPC All 35 members
Retinoids [CS] CS All 35 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
215713
Application type
ANDA · Abbreviated New Drug Application
Approval date
January 5, 2023
Sponsor
SUN PHARMA CANADA
Products on application
1
Submissions recorded
1
Products approved under application 215713.
Product Trade name Form Strength Ingredient Status TE Flags
215713-001 TRETINOIN CREAM TRETINOIN Prescription AB

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 215713.
Type No. Action Status Date Review
Original application 1 Approved January 5, 2023 Standard

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260331). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260331 HUMAN PRESCRIPTION DRUG · 20251017 HUMAN PRESCRIPTION DRUG · 20241211 HUMAN PRESCRIPTION DRUG · 20241009

Indications and Usage

openFDA Drug Labeling

Indications and Usage: Tretinoin gel and cream are indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established.

Dosage and Administration

openFDA Drug Labeling

Dosage and Administration: Tretinoin gel or cream should be applied once a day, before retiring, to the skin where acne lesions appear, using enough to cover the entire affected area lightly. Gel: Excessive application results in “pilling” of the gel, which minimizes the likelihood of over application by the patient. Application may cause a transitory feeling of warmth or slight stinging. In cases where it has been necessary to temporarily discontinue therapy or to reduce the frequency of application, therapy may be resumed or frequency of application increased when the patients become able to tolerate the treatment. Alterations of vehicle, drug concentration, or dose frequency should be closely monitored by careful observation of the clinical therapeutic response and skin tolerance. During the early weeks of therapy, an apparent exacerbation of inflammatory lesions may occur. This is due to the action of the medication on deep, previously unseen lesions and should not be considered a reason to discontinue therapy. Therapeutic results should be noticed after two to three weeks but more than six weeks of therapy may be required before definite beneficial effects are seen. Once the acne lesions have responded satisfactorily, it may be possible to maintain the improvement with less frequent applications, or other dosage forms. Patients treated with tretinoin preparations may use cosmetics, but the areas to be treated should be cleansed thoroughly before the medication is applied ( see Precautions ).

Contraindications

openFDA Drug Labeling

Contraindications: Use of the product should be discontinued if hypersensitivity to any of the ingredients is noted.

WARNINGS Keep out of reach of children. Keep tube tightly closed. Do not expose to heat. Store at 20°C to 25°C (68°F to 77°F); excursions permitted between l5°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The skin of certain sensitive individuals may become excessively red, edematous, blistered, or crusted. If these effects occur, the medication should either be discontinued until the integrity of the skin is restored, or the medication should be adjusted to a level the patient can tolerate. True contact allergy to topical tretinoin is rarely encountered. Temporary hyper- or hypopigmentation has been reported with repeated application of tretinoin cream. Some individuals have been reported to have heightened susceptibility to sunlight while under treatment with tretinoin cream. To date, all adverse effects of tretinoin cream have been reversible upon discontinuance of therapy (see Dosage and Administration). To report SUSPECTED ADVERSE REACTIONS, contact Encube Ethicals Private Limited at 1-833-285-4151 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interactions

openFDA Drug Labeling

Drug Interactions Concomitant topical medication, medicated or abrasive soaps and cleansers, soaps and cosmetics that have a strong drying effect, and products with high concentrations of alcohol, astringents, spices or lime should be used with caution because of possible interaction with tretinoin. Particular caution should be exercised in using preparations containing sulfur, resorcinol, or salicylic acid with tretinoin cream. It also is advisable to “rest” a patient’s skin until the effects of such preparations subside before use of tretinoin cream is begun.

Description

openFDA Drug Labeling

Description: Tretinoin Gel, USP and Tretinoin Cream, USP are used for the topical treatment of acne vulgaris. Each gram of tretinoin gel contains tretinoin in either of two strengths, 0.025% (0.25 mg) or 0.01% (0.1 mg) in a gel vehicle of hydroxypropyl cellulose, butylated hydroxytoluene, and alcohol 90% w/w. Each gram of tretinoin cream contains tretinoin in either of three strengths, 0.1% (1 mg), 0.05% (0.5 mg), or 0.025% (0.25 mg) in a hydrophilic cream vehicle of: stearic acid, isopropyl myristate, polyoxyl 40 stearate, stearyl alcohol, xanthan gum, sorbic acid, butylated hydroxytoluene, and purified water. Chemically, tretinoin is all-trans -retinoic acid. It has a molecular weight of 300.44 and has the following structural formula: chemical-structure-tretinoin.jpg

Overdosage: If medication is applied excessively, no more rapid or better results will be obtained and marked redness, peeling, or discomfort may occur. Oral ingestion of the drug may lead to the same side effects as those associated with excessive oral intake of Vitamin A.

How Supplied / Storage and Handling

openFDA Drug Labeling

How Supplied Tretinoin is supplied as: Tretinoin Cream NDC Code Strength/Form Qty 0378-8082-20 0378-8082-45 0.025% Cream 0.025% Cream 20 g 45 g 0378-8083-20 0378-8083-45 0.05% Cream 0.05% Cream 20 g 45 g 0378-8084-20 0378-8084-45 0.1% Cream 0.1% Cream 20 g 45 g Tretinoin Gel NDC Code Strength/Form Qty 0378-8085-15 0378-8085-45 0.01% Gel 0.01% Gel 15 g 45 g 0378-8086-15 0378-8086-45 0.025% Gel 0.025% Gel 15 g 45 g Storage Conditions: Tretinoin Gel, 0.025% and 0.01%: store below 86°F. Tretinoin Cream, 0.1%, 0.05%, and 0.025%: store below 80°F. Manufactured for: Mylan Pharmaceuticals Inc. Morgantown, WV 26505 U.S.A. Manufactured by: Bausch Health Companies Inc. Laval, Quebec H7L 4A8, Canada Revised: 02/2024 VAL:TRETCG:R2 9631002

Adverse event reports

Source: openFDA FAERS
8,793
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: TRETINOIN. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
50090-0651-0 50090-0651 A-S Medication Solutions 1 TUBE in 1 CARTON (50090-0651-0) / 20 g in 1 TUBE November 28, 2014
50090-3058-0 50090-3058 A-S Medication Solutions 1 TUBE in 1 CARTON (50090-3058-0) / 45 g in 1 TUBE June 15, 2017
50090-3128-0 50090-3128 A-S Medication Solutions 1 TUBE in 1 CARTON (50090-3128-0) / 20 g in 1 TUBE August 29, 2017
50090-4347-0 50090-4347 A-S Medication Solutions 1 TUBE in 1 CARTON (50090-4347-0) / 45 g in 1 TUBE June 11, 2019
50090-6819-0 50090-6819 A-S Medication Solutions 1 TUBE in 1 CARTON (50090-6819-0) / 45 g in 1 TUBE November 14, 2023
50090-7171-0 50090-7171 A-S Medication Solutions 1 TUBE in 1 CARTON (50090-7171-0) / 20 g in 1 TUBE May 20, 2024
0472-0117-20 0472-0117 Actavis Pharma, Inc. 1 TUBE in 1 CARTON (0472-0117-20) / 20 g in 1 TUBE April 20, 1998
0472-0117-45 0472-0117 Actavis Pharma, Inc. 1 TUBE in 1 CARTON (0472-0117-45) / 45 g in 1 TUBE April 20, 1998
62332-807-20 62332-807 Alembic Pharmaceuticals Inc. 1 TUBE in 1 CARTON (62332-807-20) / 20 g in 1 TUBE May 1, 2024
62332-807-45 62332-807 Alembic Pharmaceuticals Inc. 1 TUBE in 1 CARTON (62332-807-45) / 45 g in 1 TUBE May 1, 2024
62332-808-20 62332-808 Alembic Pharmaceuticals Inc. 1 TUBE in 1 CARTON (62332-808-20) / 20 g in 1 TUBE June 11, 2026
62332-808-45 62332-808 Alembic Pharmaceuticals Inc. 1 TUBE in 1 CARTON (62332-808-45) / 45 g in 1 TUBE June 11, 2026
62332-809-20 62332-809 Alembic Pharmaceuticals Inc. 1 TUBE in 1 CARTON (62332-809-20) / 20 g in 1 TUBE August 16, 2025
62332-809-45 62332-809 Alembic Pharmaceuticals Inc. 1 TUBE in 1 CARTON (62332-809-45) / 45 g in 1 TUBE August 16, 2025
46708-807-20 46708-807 Alembic Pharmaceuticals Limited 1 TUBE in 1 CARTON (46708-807-20) / 20 g in 1 TUBE April 25, 2025
46708-807-45 46708-807 Alembic Pharmaceuticals Limited 1 TUBE in 1 CARTON (46708-807-45) / 45 g in 1 TUBE April 25, 2025
46708-808-00 46708-808 Alembic Pharmaceuticals Limited 1 TUBE in 1 CARTON (46708-808-00) / 45 g in 1 TUBE June 11, 2026
46708-808-20 46708-808 Alembic Pharmaceuticals Limited 1 TUBE in 1 CARTON (46708-808-20) / 20 g in 1 TUBE June 11, 2026
46708-809-20 46708-809 Alembic Pharmaceuticals Limited 1 TUBE in 1 CARTON (46708-809-20) / 20 g in 1 TUBE August 16, 2025
46708-809-45 46708-809 Alembic Pharmaceuticals Limited 1 TUBE in 1 CARTON (46708-809-45) / 45 g in 1 TUBE August 16, 2025
72162-2135-2 72162-2135 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-2135-2) / 20 g in 1 TUBE June 15, 2017
72162-2135-4 72162-2135 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-2135-4) / 45 g in 1 TUBE June 15, 2017
72162-2158-2 72162-2158 Bryant Ranch Prepack 1 TUBE in 1 CARTON (72162-2158-2) / 45 g in 1 TUBE December 7, 2023
21922-077-06 21922-077 Encube Ethicals, Inc. 1 TUBE in 1 CARTON (21922-077-06) / 45 g in 1 TUBE February 13, 2026
21922-077-25 21922-077 Encube Ethicals, Inc. 1 TUBE in 1 CARTON (21922-077-25) / 20 g in 1 TUBE February 13, 2026
21922-078-06 21922-078 Encube Ethicals, Inc. 1 TUBE in 1 CARTON (21922-078-06) / 45 g in 1 TUBE March 26, 2026
21922-078-25 21922-078 Encube Ethicals, Inc. 1 TUBE in 1 CARTON (21922-078-25) / 20 g in 1 TUBE March 26, 2026
21922-079-06 21922-079 Encube Ethicals, Inc. 1 TUBE in 1 CARTON (21922-079-06) / 45 g in 1 TUBE July 11, 2025
21922-079-25 21922-079 Encube Ethicals, Inc. 1 TUBE in 1 CARTON (21922-079-25) / 20 g in 1 TUBE July 11, 2025
0378-8082-20 0378-8082 Mylan Pharmaceuticals Inc. 1 TUBE in 1 CARTON (0378-8082-20) / 20 g in 1 TUBE April 29, 2019
0378-8082-45 0378-8082 Mylan Pharmaceuticals Inc. 1 TUBE in 1 CARTON (0378-8082-45) / 45 g in 1 TUBE April 3, 2019
0378-8083-20 0378-8083 Mylan Pharmaceuticals Inc. 1 TUBE in 1 CARTON (0378-8083-20) / 20 g in 1 TUBE July 12, 2019
0378-8083-45 0378-8083 Mylan Pharmaceuticals Inc. 1 TUBE in 1 CARTON (0378-8083-45) / 45 g in 1 TUBE December 17, 2018
0378-8084-20 0378-8084 Mylan Pharmaceuticals Inc. 1 TUBE in 1 CARTON (0378-8084-20) / 20 g in 1 TUBE July 25, 2019
0378-8084-45 0378-8084 Mylan Pharmaceuticals Inc. 1 TUBE in 1 CARTON (0378-8084-45) / 45 g in 1 TUBE February 27, 2019
16714-249-01 16714-249 NORTHSTAR RX LLC 1 TUBE in 1 CARTON (16714-249-01) / 20 g in 1 TUBE February 25, 2022
16714-249-02 16714-249 NORTHSTAR RX LLC 1 TUBE in 1 CARTON (16714-249-02) / 45 g in 1 TUBE February 25, 2022
16714-250-01 16714-250 NORTHSTAR RX LLC 1 TUBE in 1 CARTON (16714-250-01) / 20 g in 1 TUBE February 25, 2022
16714-250-02 16714-250 NORTHSTAR RX LLC 1 TUBE in 1 CARTON (16714-250-02) / 45 g in 1 TUBE February 25, 2022
16714-270-01 16714-270 NORTHSTAR RX LLC 1 TUBE in 1 CARTON (16714-270-01) / 20 g in 1 TUBE January 5, 2023
16714-270-02 16714-270 NORTHSTAR RX LLC 1 TUBE in 1 CARTON (16714-270-02) / 45 g in 1 TUBE January 5, 2023
68071-3825-2 68071-3825 NuCare Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (68071-3825-2) / 20 g in 1 TUBE April 2, 2025
68071-3826-2 68071-3826 NuCare Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (68071-3826-2) / 20 g in 1 TUBE April 2, 2025
68071-3865-2 68071-3865 NuCare Pharmaceuticals,Inc. 1 TUBE in 1 CARTON (68071-3865-2) / 20 g in 1 TUBE June 10, 2025
68071-3888-2 68071-3888 NuCare Pharmaceuticals,Inc. 1 TUBE in 1 CARTON (68071-3888-2) / 20 g in 1 TUBE September 3, 2025
68071-3889-2 68071-3889 NuCare Pharmaceuticals,Inc. 1 TUBE in 1 CARTON (68071-3889-2) / 20 g in 1 TUBE September 3, 2025
68071-3945-2 68071-3945 NuCare Pharmaceuticals,Inc. 1 TUBE in 1 CARTON (68071-3945-2) / 20 g in 1 TUBE January 9, 2026
0574-2201-20 0574-2201 Padagis US LLC 1 TUBE in 1 CARTON (0574-2201-20) / 20 g in 1 TUBE March 30, 2017
0574-2201-45 0574-2201 Padagis US LLC 1 TUBE in 1 CARTON (0574-2201-45) / 45 g in 1 TUBE April 17, 2017
0574-2205-20 0574-2205 Padagis US LLC 1 TUBE in 1 CARTON (0574-2205-20) / 20 g in 1 TUBE May 5, 2017
0574-2205-45 0574-2205 Padagis US LLC 1 TUBE in 1 CARTON (0574-2205-45) / 45 g in 1 TUBE April 26, 2017
0574-2225-20 0574-2225 Padagis US LLC 1 TUBE in 1 CARTON (0574-2225-20) / 20 g in 1 TUBE June 15, 2017
0574-2225-45 0574-2225 Padagis US LLC 1 TUBE in 1 CARTON (0574-2225-45) / 45 g in 1 TUBE June 15, 2017
68788-4069-2 68788-4069 Preferred Pharmaceuticals Inc. 1 TUBE in 1 CARTON (68788-4069-2) / 20 g in 1 TUBE January 28, 2026
68788-8857-2 68788-8857 Preferred Pharmaceuticals Inc. 1 TUBE in 1 CARTON (68788-8857-2) / 20 g in 1 TUBE April 11, 2025
70518-3233-0 70518-3233 REMEDYREPACK INC. 1 TUBE in 1 CARTON (70518-3233-0) / 20 g in 1 TUBE October 11, 2021
67296-2287-4 67296-2287 Redpharm Drug 1 TUBE in 1 CARTON (67296-2287-4) / 45 g in 1 TUBE January 5, 2023
51672-1394-0 51672-1394 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1394-0) / 20 g in 1 TUBE January 25, 2019
51672-1394-9 51672-1394 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1394-9) / 45 g in 1 TUBE January 25, 2019
51672-1395-0 51672-1395 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1395-0) / 20 g in 1 TUBE January 22, 2019
51672-1395-9 51672-1395 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1395-9) / 45 g in 1 TUBE January 22, 2019
51672-1407-0 51672-1407 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1407-0) / 20 g in 1 TUBE January 5, 2023
51672-1407-9 51672-1407 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1407-9) / 45 g in 1 TUBE January 5, 2023
72578-153-08 72578-153 Viona Pharmaceuticals Inc 1 TUBE in 1 CARTON (72578-153-08) / 45 g in 1 TUBE April 30, 2024
72578-153-09 72578-153 Viona Pharmaceuticals Inc 1 TUBE in 1 CARTON (72578-153-09) / 20 g in 1 TUBE April 30, 2024
70771-1873-2 70771-1873 Zydus Lifesciences Limited 1 TUBE in 1 CARTON (70771-1873-2) / 20 g in 1 TUBE April 30, 2024
70771-1873-4 70771-1873 Zydus Lifesciences Limited 1 TUBE in 1 CARTON (70771-1873-4) / 45 g in 1 TUBE April 30, 2024
50090-0651 50090-0651 A-S Medication Solutions — April 20, 1998
50090-3058 50090-3058 A-S Medication Solutions — April 26, 2017
50090-3128 50090-3128 A-S Medication Solutions — June 15, 2017
50090-4347 50090-4347 A-S Medication Solutions — January 22, 2019
50090-6819 50090-6819 A-S Medication Solutions — January 25, 2019
50090-7171 50090-7171 A-S Medication Solutions — January 5, 2023
0472-0117 0472-0117 Actavis Pharma, Inc. — April 20, 1998
62332-807 62332-807 Alembic Pharmaceuticals Inc. — May 1, 2024
62332-808 62332-808 Alembic Pharmaceuticals Inc. — June 11, 2026
62332-809 62332-809 Alembic Pharmaceuticals Inc. — August 16, 2025
46708-807 46708-807 Alembic Pharmaceuticals Limited — April 25, 2025
46708-808 46708-808 Alembic Pharmaceuticals Limited — June 11, 2026
46708-809 46708-809 Alembic Pharmaceuticals Limited — August 16, 2025
72162-2135 72162-2135 Bryant Ranch Prepack — June 15, 2017
72162-2158 72162-2158 Bryant Ranch Prepack — April 26, 2017
21922-077 21922-077 Encube Ethicals, Inc. — February 13, 2026
21922-078 21922-078 Encube Ethicals, Inc. — March 26, 2026
21922-079 21922-079 Encube Ethicals, Inc. — July 11, 2025
0378-8082 0378-8082 Mylan Pharmaceuticals Inc. — April 3, 2019
0378-8083 0378-8083 Mylan Pharmaceuticals Inc. — November 5, 2018
0378-8084 0378-8084 Mylan Pharmaceuticals Inc. — February 27, 2019
16714-249 16714-249 NORTHSTAR RX LLC — January 25, 2019
16714-250 16714-250 NORTHSTAR RX LLC — January 22, 2019
16714-270 16714-270 NORTHSTAR RX LLC — January 5, 2023
68071-3825 68071-3825 NuCare Pharmaceuticals, Inc. — January 5, 2023
68071-3826 68071-3826 NuCare Pharmaceuticals, Inc. — January 22, 2019
68071-3865 68071-3865 NuCare Pharmaceuticals,Inc. — January 25, 2019
68071-3888 68071-3888 NuCare Pharmaceuticals,Inc. — January 5, 2023
68071-3889 68071-3889 NuCare Pharmaceuticals,Inc. — January 22, 2019
68071-3945 68071-3945 NuCare Pharmaceuticals,Inc. — June 15, 2017
0574-2201 0574-2201 Padagis US LLC — March 30, 2017
0574-2205 0574-2205 Padagis US LLC — April 26, 2017
0574-2225 0574-2225 Padagis US LLC — June 15, 2017
68788-4069 68788-4069 Preferred Pharmaceuticals Inc. — January 28, 2026
68788-8857 68788-8857 Preferred Pharmaceuticals Inc. — April 11, 2025
70518-3233 70518-3233 REMEDYREPACK INC. — October 11, 2021
67296-2287 67296-2287 Redpharm Drug — January 5, 2023
51672-1394 51672-1394 Sun Pharmaceutical Industries, Inc. — January 25, 2019
51672-1395 51672-1395 Sun Pharmaceutical Industries, Inc. — January 22, 2019
51672-1407 51672-1407 Sun Pharmaceutical Industries, Inc. — January 5, 2023
72578-153 72578-153 Viona Pharmaceuticals Inc — April 30, 2024
70771-1873 70771-1873 Zydus Lifesciences Limited — April 30, 2024

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.